News | April 12, 2024
CRISPR-based innovations drive $21 billion in pharmaceutical licensing deals over five years, reveals GlobalData
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
The drug will target specific genetic mutations prevalent in certain types of cancers
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Subscribe To Our Newsletter & Stay Updated
